Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide (the active compound in Ozempic) works by activating GLP-1 receptors in the brain and pancreas, reducing hunger signals and stabilizing blood sugar within days. Most patients report noticeable appetite suppression by week two, with measurable weight loss appearing between weeks three and four. Understanding what to expect in month one helps set realistic goals and supports long-term success.

Typical Weight Loss Results During Month One of Semaglutide Therapy

Clinical data shows that patients starting semaglutide typically lose between 2 and 4 pounds during their first month of treatment. This initial loss reflects reduced calorie intake due to appetite suppression, combined with natural water weight reduction as the body adjusts to lower food volume. The specific amount depends heavily on your starting weight, baseline metabolism, and whether you're already following a structured nutrition plan.

Week-by-week changes tend to follow a pattern: minimal change in week one as the medication enters your system, subtle appetite changes in week two, and measurable weight decline by weeks three and four. Some patients report feeling fuller faster during meals as early as day five, while others experience the appetite-suppressing effect more gradually over the full 30 days. Neither pattern is abnormal—genetic factors and individual GLP-1 receptor sensitivity account for these differences.

How Dosage and Starting Regimen Affect First-Month Outcomes

Semaglutide treatment begins with a low dose (typically 0.25 mg weekly) to minimize side effects and allow your body to adapt. Patients on this starting dose often see 1–2 pounds of weight loss in month one, while those titrated more aggressively may lose 3–4 pounds. PlexusDx personalizes your dosing strategy based on your clinical history, gastrointestinal tolerance, and treatment goals—meaning your dose may increase over time, but your price stays flat at $149 per month.

The titration schedule matters more than the absolute dose in the first month. A slower increase (0.25 mg weekly for weeks 1–4, then stepping up in month two) typically produces steadier, more tolerable weight loss. Faster escalation can accelerate results but may increase nausea or other side effects. PlexusDx clinicians match your schedule to your lifestyle and health status, ensuring sustainable progress from day one.

Metabolic and Genetic Factors That Influence Individual Response

Not every person loses weight at the same rate on semaglutide, even at identical doses. Genetic variations in your GLP-1 receptor (including the rs6923761 variant), your FTO gene (which regulates appetite signals), and your GIPR variant all influence how effectively the medication suppresses hunger and boosts metabolic rate. PlexusDx Precision Peptide Genetic Test maps these 14 pathways and 150+ genetic insights to predict your likely response and recommend the optimal compound and dosing trajectory for your biology.

Patients with genetic predispositions toward GLP-1 receptor sensitivity often experience stronger appetite suppression and faster initial weight loss. Conversely, those with certain FTO or MC4R variants may require slightly higher doses or longer adaptation periods to achieve the same results. Understanding your genetic profile in month one helps clinicians make informed adjustments to keep you on track toward your weight loss target.

Side Effects and Tolerability During the First Month

Most patients experience mild nausea, constipation, or reduced appetite during the first two weeks—these effects typically resolve by week three as the body acclimates to semaglutide. Nausea is the most common complaint, affecting 20–30% of users, but it's generally manageable with slower eating, smaller portions, and staying hydrated. Importantly, these side effects don't prevent weight loss; many patients report that mild nausea actually supports their calorie reduction goals.

A small percentage of patients (5–10%) discontinue semaglutide in month one due to intolerance, most often because of gastrointestinal upset. PlexusDx clinicians mitigate this risk by starting with the lowest effective dose, providing detailed nutrition guidance, and maintaining close communication during your first month. If you experience problematic side effects, your provider can adjust your dosing schedule or explore alternative compounds like oral semaglutide or tirzepatide.

Setting Realistic Expectations for Months Two Through Six

The first month often produces the most noticeable appetite suppression, but it's not necessarily when you'll see the largest pound-for-pound loss. Many patients experience accelerated weight loss in months two through four as doses increase and behavioral changes solidify. Monthly loss rates of 4–8 pounds become common during this window, assuming consistent adherence to dosing and nutrition plans.

Plateau periods (weeks or even a month with minimal weight change) are normal and don't signal treatment failure. Your body adapts to semaglutide, and weight loss naturally slows as you approach a new set point. PlexusDx supports long-term success by combining semaglutide therapy with genetic insights from the Precision Peptide Genetic Test, nutrition coaching, and dose adjustments that keep momentum going beyond month one. Your per-month investment remains flat—whether you're on your initial dose or a higher maintenance dose—so you can focus entirely on your health.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is 2–4 pounds in one month on semaglutide considered good progress?

Yes. First-month weight loss of 2–4 pounds is a healthy, sustainable rate that reflects appetite suppression and calorie reduction without extreme restriction. This pace typically accelerates in subsequent months as your dose increases and behavioral changes deepen. PlexusDx tracks your progress month-to-month and adjusts your treatment plan to optimize results.

Why do some people lose more weight than others in month one on the same dose?

Genetic variation is a major driver. Your GLP-1 receptor sensitivity, FTO gene expression, and MC4R pathway function all influence how strongly semaglutide suppresses appetite. PlexusDx Precision Peptide Genetic Test identifies these variants (including rs6923761, rs9939609, and rs17782313) so your clinician can predict your likely response and personalize your therapy from the start.

How much does semaglutide cost at PlexusDx?

Compounded Semaglutide Injection starts at $149 per month across all three commitment tiers—your dose may increase as treatment progresses, but your price stays flat. PlexusDx serves all 50 states, requires no insurance, and accepts HSA/FSA contributions. Add the Precision Peptide Genetic Test for $99 after your first month to unlock personalized insights.

Are nausea and constipation during month one dangerous?

Mild nausea and constipation are common and typically resolve by week three as your body adjusts. These side effects don't indicate harm; many patients find they support weight loss by naturally reducing food intake. Severe or persistent symptoms should be reported to your PlexusDx clinician immediately, who can adjust your dose or explore alternative compounds like oral semaglutide or tirzepatide.

Does the Precision Peptide Genetic Test predict my month-one weight loss?

The Precision Peptide Genetic Test doesn't predict an exact number, but it identifies genetic predispositions across 14 pathways that influence GLP-1 responsiveness, appetite regulation, and metabolic rate. This insight helps your PlexusDx clinician optimize your starting dose, titration schedule, and compound choice—setting you up for faster, more tolerable progress starting in month one.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves